Delving into the Latest Updates on Bioinova, s.r.o. with Synapse

Overview

Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the subjects were followed up as out-patients during 5 study visits for 12 months in total.

Start Date27 Aug 2013

Sponsor / Collaborator

Bioinova, s.r.o.

EUCTR2010-024665-52-CZ / Not yet recruitingPhase 2IIT

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy. - Autologous MCS effect in union of vertebrae after spinal surgery.

Start Date24 Jul 2013

Sponsor / Collaborator

Bioinova, s.r.o.

100 Clinical Results associated with Bioinova, s.r.o.

Login to view more data

0 Patents (Medical) associated with Bioinova, s.r.o.

Login to view more data

100 Deals associated with Bioinova, s.r.o.

Login to view more data

100 Translational Medicine associated with Bioinova, s.r.o.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Autologous Mesenchymal Cells(Bioinova, s.r.o.)	Osteoarthritis, Spine More	Discontinued
Mesenchymal stem cell therapy (Bioinova)	Intervertebral Disc Degeneration More	Pending